2021
Pancreatic Neuroendocrine Tumors
Muniraj T, Aslanian H. Pancreatic Neuroendocrine Tumors. 2021, 1933-1951. DOI: 10.1007/978-3-030-30192-7_81.Peer-Reviewed Original ResearchNeuroendocrine tumorsProlongs disease-free survivalDiagnosis of NETsNon-functioning neuroendocrine tumoursDisease-free survivalCareful clinical historyTreatment of choicePancreatic neuroendocrine tumorsQuality of lifeHormone hypersecretionMetastatic diseaseNonfunctional tumorsSurgical resectionTreatment modalitiesClinical historyPotential treatmentHeterogeneous groupTumorsMass effectAgeTreatmentLaboratory testsHypersecretionResectionPatients
2020
A multi-gene colorectal cancer liquid biopsy with >90% accuracy in diagnosis and assessment of disease status.
Modlin I, Kidd M, Kitz A, Drozdov I, Malczewska A, Kusnierz K, Aslanian H. A multi-gene colorectal cancer liquid biopsy with >90% accuracy in diagnosis and assessment of disease status. Journal Of Clinical Oncology 2020, 38: e16079-e16079. DOI: 10.1200/jco.2020.38.15_suppl.e16079.Peer-Reviewed Original ResearchStable diseaseColorectal cancerProgressive diseaseCA 19Cancer liquid biopsyLiquid biopsySurgical resection samplesBlood-based biomarkersCell linesResection samplesSurgical cohortSurgical resectionChemotherapy patientsCRC tumorsScore utilityClinical utilityBlood samplesColon cancerAUROC analysisDisease statusTumor tissueDiagnostic accuracyGene expressionCohortFunctional enrichment analysisPancreatic Neuroendocrine Tumors
Muniraj T, Aslanian H. Pancreatic Neuroendocrine Tumors. 2020, 1-19. DOI: 10.1007/978-3-319-90761-1_81-1.Peer-Reviewed Original ResearchNeuroendocrine tumorsProlongs disease-free survivalDiagnosis of NETsNon-functioning neuroendocrine tumoursDisease-free survivalCareful clinical historyTreatment of choicePancreatic neuroendocrine tumorsQuality of lifeHormone hypersecretionMetastatic diseaseNonfunctional tumorsSurgical resectionTreatment modalitiesClinical historyPotential treatmentHeterogeneous groupTumorsMass effectAgeTreatmentLaboratory testsHypersecretionResectionPatientsA 13-gene colorectal cancer liquid biopsy with greater than 90 percent accuracy in diagnosis and assessment of disease status.
Modlin I, Kidd M, Drozdov I, Kitz A, Malczewska A, Kusnierz K, Aslanian H. A 13-gene colorectal cancer liquid biopsy with greater than 90 percent accuracy in diagnosis and assessment of disease status. Journal Of Clinical Oncology 2020, 38: 18-18. DOI: 10.1200/jco.2020.38.4_suppl.18.Peer-Reviewed Original ResearchColorectal cancerStable diseaseProgressive diseaseClinical utilityCA 19CRC tumorsCancer liquid biopsyLiquid biopsyBlood-based biomarkersSurgical resectionChemotherapy patientsDisease burdenScore utilityBlood signatureBlood samplesAUROC analysisDisease statusDiagnostic accuracyGene expressionDiseaseCandidate markersResectionExpression levelsBiopsyCEA